Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. Biodelphis' APICore drug discovery platform enables the development of first- and best-in-class therapeutics targeting proteases. It combines the precision of targeted carriers with the potency and selectivity of peptide inhibitors to address the on-target and off-tissue toxicity limitations associated with conventional small-molecule inhibitors.

Tuesday, May 5, 15:30 - 15:45, room Singapore